BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gionchetti P, Calabrese C, Tambasco R, Brugnera R, Straforini G, Liguori G, Fornarini GS, Riso D, Campieri M, Rizzello F. Role of conventional therapies in the era of biological treatment in Crohn’s disease. World J Gastroenterol 2011; 17(14): 1797-1806 [PMID: 21528051 DOI: 10.3748/wjg.v17.i14.1797] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Yotsumoto S, Muroi Y, Chiba T, Ohmura R, Yoneyama M, Magarisawa M, Dodo K, Terayama N, Sodeoka M, Aoyagi R, Arita M, Arakawa S, Shimizu S, Tanaka M. Hyperoxidation of ether-linked phospholipids accelerates neutrophil extracellular trap formation.Sci Rep. 2017;7:16026. [PMID: 29167447 DOI: 10.1038/s41598-017-15668-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
2 Gassull MA, Cabré E. Conventional Medical Management of Crohn’s Disease: Sulfasalazine. Crohn's Disease and Ulcerative Colitis 2017. [DOI: 10.1007/978-3-319-33703-6_28] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Fornaro R, Caratto E, Caratto M, Fornaro F, Caristo G, Frascio M, Sticchi C. Post-operative recurrence in Crohn's disease. Critical analysis of potential risk factors. An update. The Surgeon 2015;13:330-47. [DOI: 10.1016/j.surge.2015.04.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
4 Wang X, Wang G, Wang J, Liu S, Zhou R, Chen L, Wu T, Huang M, Li J, Song L, Xia B. Coagulation state in patients with Crohn’s disease: the effect of infliximab therapy. European Journal of Gastroenterology & Hepatology 2014;26:955-63. [DOI: 10.1097/meg.0000000000000133] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
5 Chen QQ, Yan L, Wan J. Select a suitable treatment strategy for Crohn's disease: step-up or top-down. EXCLI J 2014;13:111-22. [PMID: 26417246] [Reference Citation Analysis]
6 Wang X, Zhou F, Zhao J, Zhou R, Huang M, Li J, Wang W, Xu S, Xia B. Elevated risk of opportunistic viral infection in patients with Crohn’s disease during biological therapies: a meta analysis of randomized controlled trials. Eur J Clin Pharmacol 2013;69:1891-9. [DOI: 10.1007/s00228-013-1559-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
7 Brown CL, Smith K, McCaughey L, Walker D. Colicin-like bacteriocins as novel therapeutic agents for the treatment of chronic biofilm-mediated infection. Biochem Soc Trans 2012;40:1549-52. [PMID: 23176515 DOI: 10.1042/BST20120241] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
8 Molnár K, Vannay &, Szebeni B, Bánki NF, Sziksz E, Cseh &, Győrffy H, Lakatos PL, Papp M, Arató A, Veres G. Intestinal alkaline phosphatase in the colonic mucosa of children with inflammatory bowel disease. World J Gastroenterol 2012; 18(25): 3254-3259 [PMID: 22783049 DOI: 10.3748/wjg.v18.i25.3254] [Cited by in F6Publishing: 23] [Reference Citation Analysis]
9 Corey K, Mattei P, Houston N, Tebbey PW, Menter A, van de Kerkhof PC, Kimball AB. Psoriasis, a proof-of-principle condition for immune-mediated inflammatory disorders: perspectives toward optimal clinical trial design. Clinical Investigation 2012;2:671-678. [DOI: 10.4155/cli.12.57] [Reference Citation Analysis]